KERENDIA

Peak

finerenone

NDAORALTABLETPriority Review
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
40

Mechanism of Action

Mineralocorticoid Receptor Antagonists

Pharmacologic Class:

Nonsteroidal Mineralocorticoid-Receptor Antagonist

Clinical Trials (5)

NCT07192952Phase 3Not Yet Recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

Started Apr 2026
117 enrolled
Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)
NCT07379840N/ARecruiting

A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea

Started Dec 2025
300 enrolled
Chronic Heart Failure
NCT07270367Phase 3Not Yet Recruiting

Finerenone and Cardiac Remodeling

Started Dec 2025
156 enrolled
Heart Failure
NCT07232537N/ARecruiting

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

Started Nov 2025
500 enrolled
Chronic Kidney DiseaseType 2 Diabetes Mellitus
NCT07188805Phase 3Recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

Started Nov 2025
111 enrolled
Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)

Loss of Exclusivity

LOE Date
Jul 29, 2035
114 months away
Patent Expiry
Jul 29, 2035
Exclusivity Expiry
Jul 11, 2028

Patent Records (2)

Patent #ExpiryTypeUse Code
8436180
Aug 26, 2033
SubstanceProduct
RE49826
Jul 29, 2035
Substance